Our Company

OUR COMPANY

Our Company

In a nutshell

Da Volterra is a private clinical-stage biopharmaceutical company which innovates for better health and care for people worldwide.

Our team is composed of 45 people with an extensive experience in science and in the industrial development of medical products. Together, we are dedicated to developing novel and safe therapeutic options for patients.

Our expertise focuses on the protection of the intestinal microbiome during antibiotic treatments.

  • Based in Paris, France
  • 45 collaborators,
    14 PhD
  • 81M€ funds raised
  • Lead Microbiome Protector in Phase 3

Our goal

Da Volterra’s goal is to develop and commercialize innovative healthcare solutions to preserve the intestinal microbiome of patients worldwide and help prevent and cure life-threatening diseases.

As new insights into the human intestinal microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, Da Volterra is a pioneer in understanding and harnessing the microbiome capacity to help prevent and cure diseases, notably in cancer patients.

Our mission & vision

Da Volterra’s vision is to be a trusted and acknowledged leader of drug and medical device development in the microbiome field.

Our mission is to discover and develop up-to-market safe and novel therapeutic options, preserving patients’ microbiome to prevent and cure life-threatening diseases.

We strive to serve patients by transforming the promise of science into innovative treatments which have the power to restore health and save lives.

History

The company was created by Professor Antoine Andremont whose life-long research was dedicated to antibiotic resistance and understanding the impact of antibiotics on the intestinal microbiome.

2000

Company inception

Prof. Antoine Andremont creates Da Volterra based on concepts originating from his work on the impact of antibiotics on the intestinal microbiome and antibiotic resistance. Academic collaborations are set-up to explore early research work.

2006

Early academic collaboration and technology patent filling

The first patents are granted on innovative approaches to protect the intestinal microbiome and spare patients from life-threatening bacterial infections. Further innovations are developed later on with new patent applications filed regularly by the R&D team.

2009

Company structuration

The team is building up and takes foot in its facilities and laboratories of the rue de Charonne in Paris.
The management team is formed and 10 employees are recruited.

2014

DAV132 proof of concept

The proof-of-concept of DAV132 is achieved in humans treated with antibiotics in a series of phase 1 clinical studies:
– No interaction with antibiotic efficacy
– Free antibiotic faecal concentrations decreased by 99%
– Very good protection of the microbiome diversity

2015

DAV132 reaches 1st major
regulatory milestones

CE mark granted in Europe (ISO13485) and Pre-IND meeting with the FDA clears the development path as a drug in the USA.

2018

Microbiome and Immuno-Oncology

First publications highlighting the role of microbiome and the impact of antibiotics on the efficacy of immune checkpoints inhibitors in cancer patients.

2019

Completion of the phase 2 clinical trial evaluating DAV132 in patients

Success of the phase 2 clinical trial (SHIELD) evaluating DAV132 in patients.

The SHIELD trial showed that DAV132 was safe for use in hospitalized elderly patients with several comorbidities and taking concomitant medications. It also demonstrated that DAV132 was able to protect the intestinal microbiome from antibiotic damage.

It is the first phase 2 clinical trial assessing DAV132 safety and ability to protect the intestinal microbiome in patients.

2021

Launch of the Phase 3 clinical trial evaluating DAV132 in hemato-oncology patients

The overarching objective of the MICROCARE trial is to demonstrate that DAV132 contributes to decrease the occurrence of life-threatening complications and to reduce the mortality of patients with hematologic malignancies undergoing several cycles of chemotherapies. 900 patients will be enrolled in Europe and the US.